APS 2021 infographic: Innovating in rare neurometabolic disorders: A focus on AADC deficiency
View the infographic distributed by PTC Therapeutics at the APS 2021 Symposium, which introduces aromatic L-amino acid decarboxylase (AADC) deficiency, outlines key diagnostic steps in clinical practice, and discusses gene therapies in development
Recognize the key signs and symptoms for AADC deficiency to aid early identification of this rare disease in clinical practice
Understand the core diagnostic tests recommended by international consensus guidelines for diagnosis
Find out about the potential role of gene therapy treatments in development for patients with AADC deficiency
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-AADC-2200021 | March 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.